Published in Pancreas on March 01, 1990
A perspective of polyamine metabolism. Biochem J (2003) 3.24
Radiation metabolomics. 4. UPLC-ESI-QTOFMS-Based metabolomics for urinary biomarker discovery in gamma-irradiated rats. Radiat Res (2011) 1.46
The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res (2011) 1.30
Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Cancer Prev Res (Phila) (2014) 0.91
activated polyamine catabolism in acute pancreatitis: alpha-methylated polyamine analogues prevent trypsinogen activation and pancreatitis-associated mortality. Am J Pathol (2006) 0.82
Genetic polymorphism in ornithine decarboxylase and risk of breast cancer. Fam Cancer (2009) 0.81
Cellular diamine levels in cancer chemoprevention: modulation by ibuprofen and membrane plasmalogens. Lipids Health Dis (2011) 0.78
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut (2004) 5.32
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest (1993) 5.06
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia (1986) 4.54
Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. The German Study Group on Acute Biliary Pancreatitis. N Engl J Med (1997) 4.18
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology (1993) 3.98
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1993) 3.63
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab (1986) 2.80
Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut (1996) 2.41
The incretin concept today. Diabetologia (1979) 2.18
[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. Z Gastroenterol (2004) 2.03
Histopathological classification of nonantral gastric endocrine growths in man. Digestion (1988) 1.85
Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion (1987) 1.73
Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol (1989) 1.72
Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. Digestion (1993) 1.71
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab (1996) 1.70
Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia (1985) 1.67
Influence of feeding and sham feeding upon serum gastrin and gastric acid secretion in control subjects and duodenal ulcer patients. Scand J Gastroenterol (1974) 1.63
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab (1993) 1.61
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 1.53
Gastrin and G-cells in the antral mucosa of patients with pernicious anaemia, acromegaly and hyperparathyroidism and in a Zollinger-Ellison tumour of the pancreas. Eur J Clin Invest (1971) 1.52
Comparative clinical evaluation of the 13C-mixed triglyceride breath test as an indirect pancreatic function test. Scand J Gastroenterol (1998) 1.49
Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. Scand J Gastroenterol (2001) 1.47
Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene (2001) 1.46
Mucosal gastrin concentration, molecular forms of gastrin, number and ultrastructure of G-cells in patients with duodenal ulcer. Gut (1976) 1.42
Primary sclerosing cholangitis mimicking choledocal cyst type 1 in a young patient. Endoscopy (1999) 1.41
[Hepatosplenomegaly]. Internist (Berl) (1994) 1.40
Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut (2002) 1.40
[Therapy of chronic pancreatitis]. Dtsch Med Wochenschr (1996) 1.39
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia (1996) 1.37
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion (1988) 1.34
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene (2009) 1.32
Aetiology and pathogenesis of pancreatitis. (Current concepts). Scand J Gastroenterol Suppl (1970) 1.29
Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev (1987) 1.27
Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene (2006) 1.27
The influence of glucagon on acute experimental pancreatitis in the rat. Scand J Gastroenterol (1974) 1.26
Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia (1984) 1.23
Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipatrophic diabetes. Humangenetik (1975) 1.22
Hypoglycaemia. 1. Insulin secreting tumours. Clin Endocrinol Metab (1976) 1.22
Expression of the NF-kappa B target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells. Oncogene (2001) 1.22
Liver diseases and diabetes mellitus. Prog Liver Dis (1970) 1.21
S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol (2010) 1.20
Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome). Hum Pathol (1975) 1.20
Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab (1989) 1.17
Enteral long-term nutrition via percutaneous endoscopic gastrostomy (PEG) in 210 patients: a four-year prospective study. Dig Dis Sci (1998) 1.17
New developments in the incretin concept. Diabetologia (1985) 1.15
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol (2001) 1.13
Myo-, neuro-, gastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome-c-oxidase. A new mitochondrial multisystem disorder. Acta Neuropathol (1987) 1.13
Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut (2002) 1.11
Biochemical and morphological investigations of 30 human insulinomas. Correlation between the tumour content of insulin and proinsulin-like components and the histological and ultrastructural appearance. Diabetologia (1973) 1.10
Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol (1995) 1.09
Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr (1988) 1.09
Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion (1990) 1.09
Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia (1980) 1.08
Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion (1988) 1.08
Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats. Diabetologia (1984) 1.07
Somatostatin and insulin release from isolated rat pancreatic islets stimulated by glucose. FEBS Lett (1976) 1.07
Inhibition of gastric secretion by calcitonin in man. Horm Metab Res (1971) 1.06
Functional expression of HGF and its receptor in human colorectal cancer. Digestion (2000) 1.05
Pancreatic enzyme response to secretin and cholecystokinin-pancreozymin in the rat. J Physiol (1973) 1.05
Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J (2002) 1.05
Gastric inhibitory polypeptide (GIP), gastrin and insulin: response to test meal in coeliac disease and after duodeno-pancreatectomy. Diabetologia (1976) 1.05
Somatostatin and the stomach: exocrine and endocrine aspects. Metabolism (1978) 1.04
[Calcitonin-induced inhibition of exocrine pancreatic secretion in man]. Dtsch Med Wochenschr (1971) 1.04
Mechanisms in failure of infliximab for Crohn's disease. Lancet (2000) 1.03
Analysis of the inhibitory effect of biguanides on glucose absorption: inhibition of active sugar transport. Diabetologia (1971) 1.02
[S3-Consensus guidelines on definition, etiology, diagnosis and medical, endoscopic and surgical management of chronic pancreatitis German Society of Digestive and Metabolic Diseases (DGVS)]. Z Gastroenterol (2012) 1.02
Mechanism of insulin resistance in CCl4-induced cirrhosis of rats. Gastroenterology (1992) 1.02
Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J (2005) 1.01
Chylous cardiac tamponade in acute pancreatitis. Dig Dis Sci (1996) 1.01
[Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecystokinin-pancreozymin administration (author's transl)]. Dtsch Med Wochenschr (1975) 1.01
The possible role of phospholipase A in the pathogenesis of acute pancreatitis. Scand J Gastroenterol (1969) 1.01
The pancreatic secretion of enzymes in rats treated with soybean diet. Scand J Gastroenterol (1974) 1.00
Influence of repeated administration of cholecystokinin and secretin on the pancreas of the rat. Scand J Gastroenterol (1978) 0.98
Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia (1978) 0.98
Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease. Gastroenterology (1998) 0.98
Adaptation of the pancreas during treatment with enzyme inhibitors in rats and man. Scand J Gastroenterol Suppl (1985) 0.98
CCK-B/gastrin receptors in human colorectal cancer. Eur J Clin Invest (2001) 0.98
Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide. Am J Physiol (1991) 0.98
[Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease]. Z Gastroenterol (2004) 0.97
Dietary polyamines are essential luminal growth factors for small intestinal and colonic mucosal growth and development. Gut (1999) 0.97
Antral gastrin-producing G-cells and somatostatin-producing D-cells in different states of gastric acid secretion. Gut (1982) 0.97
Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion (1982) 0.97
[Hypoglycemia factitia. A differential diagnostic significant form of hyperinsulinism]. Dtsch Med Wochenschr (1969) 0.97
Role of cholecystokinin in the negative feedback control of pancreatic enzyme secretion in conscious rats. Gastroenterology (1987) 0.96
Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. Digestion (1986) 0.96
Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology (1979) 0.95
Functional disruption of IEX-1 expression by concatemeric hammerhead ribozymes alters growth properties of 293 cells. FEBS Lett (2001) 0.95
The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition. Oncogene (2007) 0.94
The morphological substrate of the inhibition of insulin secretion by diazoxide. Horm Metab Res (1969) 0.94
Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis. Gut (1990) 0.94
Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol (1987) 0.93
Gastrointestinal somatostatin: extraction and radioimmunoassay in different species. Gut (1978) 0.93
Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene (2006) 0.93
Somatostatin therapy of acute experimental pancreatitis. Gut (1977) 0.93